BostonGene Announces Ten Presentations at the 65th American Society of Hematology Annual Meeting & Exposition Presentations with Leading Institutions Reveal BostonGene’s AI-driven Molecular and ...
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced ...
Collaborative Presentations Showcase BostonGene’s AI-Driven Innovations in Molecular and Immunoprofiling as Essential for Advancing Cancer Therapies Through Microenvironment and Immune Cell ...
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results